Boston Scientific Faces Class Action Over Alleged Misleading Statements and Poor Financial Performance
Boston Scientific Corporation is facing a class action lawsuit alleging that the company provided misleading statements about its U.S. EP segment's growth, leading to a significant stock price drop. The company's stock fell by approximately 17.6% following the release of disappointing financial results and guidance for fiscal 2026. The lawsuit claims management was aware of unsustainable growth in the segment but failed to disclose this information to investors.
Tickers: $BSX
Topics: class action earnings miss financial fraud misleading statements stock price decline